Our purpose is to halt the deadly progression of atherosclerosis and the cardiovascular risk created by high levels of LDL-C
. The Company is headquartered in Parsippany, New Jersey.
The primary endpoints are %age change in LDL-C
from baseline to day 510 (17 months) and time-adjusted %age change in LDL-C
from baseline after day 90 (three months) and up to day 540 (18 months).
We found positive correlations between LDL-C
and LDL-1 (r=0.541, p<0.001) and also between LDL-2 (r=0.682, p<0.001), LDL-3 (r=0.484, p<0.001) and LDL-4 (r=0.347, p<0.001).
The pre-requisite at the time of enrolment was that patients should have an LDL-C
level >70 mg/dl.
There were significant differences between the low- and high-LDL-C/HDL-C groups in TG, TC, LDL-C
, HDL-C, TG/HDL-C ratio, diabetes, smoking, alcohol, family history of premature CHD, and vessel lesions, which were included in multivariate Cox regression analysis, as well as LDL-C/HDL-C ratio (the categorical variable).
Physiologically, apoB is arguably more relevant than LDL-C
. Cardiovascular disease is the result of lipid plaques within artery walls.
The obvious questions include what role or association LDL-c
and non-HDL-c have with IR and with components of MS.
level of less than 50 mg/dl is considered low while a level of less than 20 mg/dl is considered extremely low.
There was a significant reduction in deaths from coronary disease and a further reduction in major vascular events (non-fatal myocardial infarction, fatal coronary heart disease, coronary artery bypass surgery, percutaneous transluminal coronary angioplasty, and ischaemic stroke) which equated to a 22% reduction per 1 mmol/L of LDL-C
. All current clinical data support the belief that LDL-C
and its atherogenic subfractions are the real target for reducing CVD risk.
The company's drug was found to reduce LDL-C
by a mean of 76.5%, with 30% of patient participants seeing a greater than 90% reduction.
This paper describes these patients with respect to serum PCSK9 concentrations, catabolic determinants including apolipoprotein and lipid fractions, resultant LDL-C
, other atherogenic lipid particles, the effect of PCSK9 on LDL, and factors contributing to PCSK9.